|
Collaborative and Other Agreements (Details) (USD $)
|
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Licensing and collaboration agreement revenue | $ 263,000us-gaap_LicenseAndServicesRevenue | $ 964,000us-gaap_LicenseAndServicesRevenue |
| Royalties paid, minimum (in hundredths) | 0.50%xoma_RoyaltiesPaidPercentageMinimum | |
| Royalties paid, maximum (in hundredths) | 5.00%xoma_RoyaltiesPaidPercentageMaximum | |
| Collaborative Arrangement [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Eligible milestone payments receivable |
433,000,000xoma_EligibleMilestonePaymentsReceivable / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Eligible milestone payments receivable under specific rights not met |
770,000,000xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMet / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Eligible milestone payments receivable, after amendment |
415,000,000xoma_EligibleMilestonePaymentsReceivableAfterAmendments / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Eligible milestone payments receivable under specific rights not met, after amendment |
752,000,000xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMetAfterAmendment / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Collaborative Arrangement [Member] | Servier Loan [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Future initial research and development expenses to be funded by counterparty |
50,000,000xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterpartyUnderCollaborativeArrangement / us-gaap_DeferredRevenueArrangementTypeAxis = xoma_ServierLoanMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Licensing and collaboration agreement revenue |
$ 500,000us-gaap_LicenseAndServicesRevenue / us-gaap_DeferredRevenueArrangementTypeAxis = xoma_ServierLoanMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
$ 900,000us-gaap_LicenseAndServicesRevenue / us-gaap_DeferredRevenueArrangementTypeAxis = xoma_ServierLoanMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
| Collaborative Arrangement [Member] | Symplmed Pharmaceuticals [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Royalties paid, minimum (in hundredths) |
3.00%xoma_RoyaltiesPaidPercentageMinimum / us-gaap_DeferredRevenueArrangementTypeAxis = xoma_SymplmedPharmaceuticalsMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| Royalties paid, maximum (in hundredths) |
10.00%xoma_RoyaltiesPaidPercentageMaximum / us-gaap_DeferredRevenueArrangementTypeAxis = xoma_SymplmedPharmaceuticalsMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the eligible milestone payments receivable. No definition available.
|
| X | ||||||||||
|
- Definition
Represents eligible milestone payments receivable after amendments. No definition available.
|
| X | ||||||||||
|
- Definition
Represents eligible milestone payments receivable under specific rights not met. No definition available.
|
| X | ||||||||||
|
- Definition
Represents Eligible milestone payments receivable under specific rights not met after amendment. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty under a collaborative arrangements. No definition available.
|
| X | ||||||||||
|
- Definition
The maximum percentage of royalties paid to selling price of licensed components. No definition available.
|
| X | ||||||||||
|
- Definition
The minimum percentage of royalties paid to selling price of licensed components. No definition available.
|
| X | ||||||||||
|
- Details
|